|
|
|
02 Jun 2008 |
Biovex reports positive phase II clinical trial results of Oncovexgm-CSF in metastatic melanoma at the 2008 American Society of Clinical Oncology Meeting
|
|
02 Jun 2008 |
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
|
|
02 Jun 2008 |
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
|
|
02 Jun 2008 |
CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
|
|
30 May 2008 |
BioAlliance Pharma Presents New Results on its AMEP(TM) anti-invasive biotherapy
|
|
30 May 2008 |
Antisoma announces positive ASA404 presentations at ASCO
|
|
30 May 2008 |
Genasense(R) Chemotherapy Program Yields High Response Rate in Patients with Stage 4 Melanoma
|
|
30 May 2008 |
New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma
|
|
30 May 2008 |
Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
|
|
30 May 2008 |
Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer
|
|
30 May 2008 |
Genmab initiates Zalutumunab combination study in Colorectal Cancer
|
|
30 May 2008 |
TransMolecular Initiates Phase 1 Clinical Trial for Unlabeled TM601 in Recurrent Malignant Glioma
|
|
29 May 2008 |
Vall d’Hebron University Hospital and Cyclacel to initiate Phase 1 combination study of Seliciclib and Tarceva(R)
|
|
29 May 2008 |
AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell Carcinoma
|
|
29 May 2008 |
Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
|
|
29 May 2008 |
GlaxoSmithKline announces new drug application and Phase III results for Rezonic(TM) / Zunrisa(TM) (casopitant)
|
|
29 May 2008 |
Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
|
|
28 May 2008 |
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
|
|
28 May 2008 |
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
|
|
28 May 2008 |
BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancerin Uterine Cancer
|
|
27 May 2008 |
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
|
|
27 May 2008 |
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
|
|
23 May 2008 |
GTx Announces Phase III PIN Clinical Trial Will Continue As Planned
|
|
22 May 2008 |
ARIAD Initiates Phase 1 Clinical Trial of its Investigational Oral Multi-Targeted Kinase Inhibitor, AP24534, in Patients with Hematological Cancers
|
|
21 May 2008 |
Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
|
|
21 May 2008 |
Cell Genesys Reports Encouraging Interim Data From Phase 1 Clinical Trial of CG0070 in Recurrent Bladder Cancer
|
|
21 May 2008 |
Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology
|
|
21 May 2008 |
NeoPharm Enrolls First Patient in Phase I Trial for Patients with Metastatic Solid Cancer
|
|
21 May 2008 |
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
|
|
20 May 2008 |
Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient Enrollment
|
|
19 May 2008 |
Patient recruitment started in Phase III registration trial with CA9-SCAN
|
|
19 May 2008 |
RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer
|
|
19 May 2008 |
New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) For Injection Based Therapies In Patients With Newly Diagnosed Multiple Myeloma
|
|
19 May 2008 |
Gloucester Pharmaceuticals Announces Positive Results from Phase 2b Registration Trial of Romidepsin in Refractory CTCL
|
|
16 May 2008 |
Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent
|
|
16 May 2008 |
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
|
|
16 May 2008 |
The GI Company Reports Significant Reduction in Occurrence of Oral Mucositis in Phase II Study; Abstract Posted Online at ASCO.org
|
|
16 May 2008 |
Genentech Provides Update On Studies Of Investigational Biooncology Agents To Be Presented At The American Society Of Clinical Oncology Meeting
|
|
16 May 2008 |
GSK announces results of first Phase III trial evaluating Tykerb(R)/Tyverb(R) (lapatinib) plus Herceptin(R) (trastuzumab)
|
|
16 May 2008 |
ZymoGenetics Announces Publication of Five IL-21 ASCO Abstracts
|
|
16 May 2008 |
Array BioPharma and AstraZeneca Announce New Phase 2 Development Plans for the Investigational Anti-Cancer Drug AZD6244 (ARRY-886)
|
|
16 May 2008 |
E7389 Demonstrated Anti-tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
|
|
16 May 2008 |
ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
|
|
16 May 2008 |
ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line Setting
|
|
16 May 2008 |
OncoGenex reports updated survival data on OGX-011 in a second-line chemotherapy trial for patients with prostate cancer
|
|
16 May 2008 |
Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
|
|
15 May 2008 |
Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial
|
|
15 May 2008 |
Progen Resumes Phase I development of Anti-Cancer Agent, PG-11047
|
|
13 May 2008 |
Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial
|
|
13 May 2008 |
Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient Enrollment
|
| |
|
Results 401 - 450 of 2757 |
